Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Briacell Therapeutics Corp. T.BCT

Alternate Symbol(s):  BCTX | BCTXW

Healthcare Biotechnology
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II... see more

Recent & Breaking News (TSX:BCT)

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+(TM) and Bria-PROS+(TM) Clinical Candidates for Breast and Prostate Cancer

GlobeNewswire 9 days ago

BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR

GlobeNewswire 10 days ago

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

GlobeNewswire March 7, 2024

BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference

GlobeNewswire March 6, 2024

BriaCell Provides Update on Alleged Illegal Trading of Public Securities

GlobeNewswire February 27, 2024

BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

GlobeNewswire February 7, 2024

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

GlobeNewswire February 6, 2024

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

GlobeNewswire January 30, 2024

BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with "Eye-Bulging" Metastatic Breast Cancer

GlobeNewswire January 4, 2024

BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

GlobeNewswire December 28, 2023

BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset

GlobeNewswire December 20, 2023

BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

GlobeNewswire December 6, 2023

BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit

GlobeNewswire December 6, 2023

BriaCell Records New Responder with Remarkable Improvement of "Eye-Bulging" Metastatic Tumor

GlobeNewswire November 30, 2023

BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS(TM) IND

GlobeNewswire November 3, 2023

BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate

GlobeNewswire October 25, 2023

October is Breast Cancer Awareness Month - BriaCell is Leading the Fight with its Innovative Technology

GlobeNewswire October 20, 2023

BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences

GlobeNewswire October 18, 2023

BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT(TM) Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic

GlobeNewswire October 11, 2023

BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT(TM) in Advanced Breast Cancer

GlobeNewswire October 4, 2023